RSL Revolutionary Labs Ltd, a pioneer in offering unique skincare formulations tailored specifically for oncology patients under their innovative brand, εὖSKIN®, is pleased to announce a strategic partnership with Smedo for the distribution of its revolutionary product line in Greece.
Dedicated to redefining skincare management, RSL has collaborated closely with esteemed scientists, dermatologists, and oncology specialists to develop εὖSKIN® – a groundbreaking range of dermaceutical solutions. These advanced formulas undergo rigorous validation, including extensive research and development, preclinical studies, and clinical data analysis, ensuring the provision of the best possible solutions for patients’ unique needs.
With over 15 natural ingredients and biomaterials, including molecularly engineered atelocollagen peptides, εὖSKIN® is designed to address the diverse challenges faced by oncology patients undergoing treatment. RSL’s ultimate goal is to improve the lives of those affected by cancer by providing effective and innovative skincare solutions.
Under the distribution agreement, Smedo will make the εὖSKIN® product line available through its e-shop, www.smedo.gr, providing Greek consumers with access to advanced dermaceutical solutions designed to prevent and care for sensitive affected skin, address damaged nails, and alleviate mucosal side effects.
